TOL-3021

Phase 2Biologic

TTolerion, Inc.

TOL-3021 is one of 5 biologic programs targeting Autoimmunity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AutoimmunityWithdrawn

AutoimmunityPhase 2

Withdrawn

Competition

Competitive Landscape

5 competitors in Autoimmunity

#DrugCompanyPhaseTrials

Skyrizi

AbbVie

Approved

1 2

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 4

Prednisone and Aspirin

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

2 5

TOL-3021

TTolerion, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Autoimmunity3 trials

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)

Withdrawn·TTolerion, Inc.·Phase 2·NCT03794960

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

Withdrawn·TTolerion, Inc.·Phase 2·NCT03794973

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Active, not recruiting·TTolerion, Inc.·Phase 2·NCT03895437·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TOL-3021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TOL-3021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TOL-3021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tolerion, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TTolerion, Inc.

TOL-3021

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Autoimmunity3 trials

References

Drug Info

Quick Facts

Related News